418O Phase 1b study of the safety and antitumour activity of durvalumab (MEDI4736) + tremelimumab in advanced NSCLC

Authors :: Naiyer A. Rizvi
Joyson Joseph Karakunnel
Rachel E. Sanborn
Sarah B. Goldberg
S.J. Antonia
Marlon Rebelatto
Jamie E. Chaft
Rajesh Narwal
Yu Gu
Ani Sarkis Balmanoukian
Paul B. Robbins
Source :: Annals of Oncology. 26:ix125
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Oncology
medicine.medical_specialty
Durvalumab
business.industry
Internal medicine
medicine
Hematology
business
Tremelimumab
medicine.drug

Full Text Access

Tools